banner
 
bar

program

slides
bar
 
 

Optimizing Management of the
Diabetic Heart

WebCAST

Viewer Survey
How long did you spend on this program?

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in managing patients with diabetes.

Release Date

August 18, 2016

Expiration Date

August 18, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period August 18, 2016 through August 18, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Commercial Support

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Advancing Knowledge in Healthcare and CMEducation Resources, LLC. Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME

Disclosure of Conflicts of Interest

(AKH) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to AKH policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity

Program Faculty and Disclosure

VIVIAN A. FONSECA, MD, FRCP
(Program Co-Chair)

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Honoraria received for consulting and lectures - Amgen, AstraZeneca, Eli Lilly, Janssen, Novo Nordisk, Sanofi-aventis, Takeda


DEEPAK L. BHATT, MD, MPH, FACC, FAHA, FSCAI, FESC
(Program Co-Chair)

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA

Contracted Research: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Ischemix, Medtronic, Pfizer, Roche, Sanofi-aventis, The Medicines Company


R. SCOTT WRIGHT, MD
Professor of Medicine
Cardiovascular Division
Mayo Clinic
Rochester, Minnesota

Consultant - AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi Regeneron, The Medicines Company


JAMES M. McKENNEY, PharmD
Emeritus Professor
Virginia Commonwealth University
CEO
National Clinical Research, Inc.
Richmond, VA

Nothing to disclose

AKH STAFF/REVIEWERS

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Project Manager/Reviewer: has disclosed no relevant financial relationships.
Kelly Kraines, AKH Senior Director - Projects and Planning, Planner/Reviewer: has disclosed no relevant financial relationships

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Detail the mechanisms, trials, and translational implications of identifying new LDL targets that have the potential for producing LDL reductions above those that can be achieved with current statin-lowering agents
  • Evaluate treatment options in diabetic patients who are intolerant to or unable to take statins, and who require additional LDL lowering to optimize CV risk reduction
  • Discuss the epidemiology, disease burden, scientific knowledge base, and landmark trials that explain the central importance of cardiovascular disease as a dreaded complication of, and comorbid condition associated with, diabetes Deploy and appropriately sequence pharmacologic interventions that can optimize CV risk reduction in patients with diabetes ?
  • Detail the clinical implications of the multiple molecular mechanisms, biomarkers, and cardiometabolic risk factors (hyperlipidemia, hyperglycemia, increased weight, hypertension, postprandial hyperglycemia, and others) that underlie development of cardiovascular disease in diabetic patients ?
  • Apply the Year 2012 ADA/EASD guidelines for T2D management, with a focus on the cardiovascular dimensions of diabetes care
  • Explain why PCSK9 and APOB have emerged as an attractive target for the development of LDL lowering agents, either alone or in combination with statins, in the setting of high risk patients with diabetes and other subgroups with high hereditary-based increases in LDL levels

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

Abetalipoproteinemia
AEGR-733
Anacetrapib
Allele
Antisense Oligonucleaotide
apheresis
Apo B
Apo B-100
ASO
Atheroprotection
Atorvastatin CETP
cholesterol

Dutch Lipid Clinic Network Diagnostic Criteria
Ezetimibe
Familial Hyperlipidemia
FH
HDL
Heterozygous
homozygous
Hypercholesterolemia
LDL
LDLR
Lomitapide

 

Lp(a)
mAb
MEDPED
Microsomal Triglyceride Transport Protein
Mipomersen
MTP
NCEP ATP III
PCSK9
PCSK9 Inhibitors
REGN727 niacin
REGN727/SAR236553

Rosuvastatin
SAR236553
Simon Broome
Statin
tendon xanthoma
UK NICE FH Guidelinesdulation
Neurosyphilis
NIMO
NMSS
Novantrone